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Abstract
The c-Raf – MEK1/2 – ERK1/2 mitogen-activated protein kinase (MAPK) intracellular signalling cascade in neurons plays
important roles in the control of a variety of behaviours, including social behaviours and anxiety. These roles partially
overlap with those described for oxytocin (OXT), and it has been shown that OXT activates the MAPK pathway in the
hypothalamus (of male), and hippocampus (of female) rats. Here, by combining behavioural (light/dark box) and
biochemical analyses (western blotting), we tested two hypotheses: (i) that OXT is anxiolytic within the hypothalamus of
females, and (ii) that this effect, as well as that of lactation-associated anxiolysis, depends on the recruitment of the MAPK
pathway. We found that, when injected bilaterally into the hypothalamic paraventricular nucleus (PVN), OXT decreased
anxiety-like behaviour in virgins, and that this effect depended on phosphorylation of MEK1/2. MAPK pathway activation in
lactation was evident by high phosphorylated (p) MEK1/2 levels, and nuclear translocation of ERK1. The high pMEK1/2 levels
were necessary for the anxiolytic phenotype typically observed during lactation. Interestingly, exogenous OXT in lactating
rats reduced pMEK1/2 levels without a concomitant effect on anxiety, indicating that OXT receptor activation can lead to
recruitment of additional intracellular pathways to modulate MEK activity. Still other pathways could include MEK, but
without subsequent activation of ERK, as we did not observe any increase in OXT-induced ERK phosphorylation. Together
the results demonstrate that the MAPK pathway, especially MEK1/2, is critically involved in the regulation of anxiety-like
behaviour in female rats.
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Introduction
The c-Raf – MEK1/2 – ERK1/2 mitogen-activated protein
kinase (MAPK) pathway is one of the most important and best-
studied intracellular signalling pathways. This pathway conveys
extracellular signals to intracellular effectors via activation of a
variety of cell membrane receptors, and hence is responsible for
a battery of effects. In the brain, extracellular signal-regulated
kinases (ERK) are strongly activated by synaptic stimulation, and
are essential for the induction and maintenance of synaptic
plasticity that is thought to underlie memory and learning [1].
Furthermore, ERKs have been shown to regulate anxiety-like
behaviour and to contribute to the control of social behaviours,
including social memory and aggression, particularly via ERK2
[2]. These effects overlap, at least partially, with those reported
for the neuropeptide oxytocin (OXT), and indeed it has been
shown that OXT activates the MAPK pathway within the
hypothalamic paraventricular nucleus (PVN) via transactivation
of the epidermal growth factor receptor (EGFR) to regulate
anxiety in male rats [3]. Interestingly, the related nonapeptide,
arginine vasopressin (AVP), has been shown to activate the
MAPK pathway in vitro [4] but did not alter its activity within the
PVN when applied in vivo [3]. Further, it has been repeatedly
demonstrated that exogenous central administration of AVP has
an anxiogenic effect [5] and that its expression level within the
PVN negatively correlates with anxiety-related behaviour [6,7].
In females, the brain OXT system is particularly active during
the peripartum period with elevated rates of synthesis of the
neuropeptide and its receptor, enhanced local release, and
receptor binding within limbic and hypothalamic regions (for
review see [8,9,10]). Such high brain OXT levels are important
to induce anxiolysis during lactation [11,12]. Also, OXT
enhances spatial memory in the hippocampus of lactating rats,
thought to improve the recollection of locations where food and
water are present, and thus to reduce the time the mother needs
to spend finding resources and leaving the pups unattended [13].
This effect of OXT on spatial memory depends on the activation
of ERK, and one of its downstream effectors, the CRE
responsive element binding protein (CREB) [13]. This example,
together with the anxiolytic effect described above in males,
shows the importance of ERK and its kinase MEK as
intracellular mediators of the behavioural effects of OXT
signalling. Further, it shows that the MAPK signalling pathway
is recruited during lactation in the hippocampus, and that its
recruitment depends on OXT. Moreover, given lactation-
associated anxiolysis, and the role of both OXT and MAPK in
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the roles of MEK and ERK in the PVN of females as effectors of
anxiety-related behaviour have not been reported to date. This is
nevertheless of particular importance considering the mood
changes that frequently occur at peripartum in humans ([9] and
references therein), and the reported pro-social and anxiolytic
effects of OXT in males and females, in rats as well as in humans
[3,5,14,15,16,17].
Therefore, the present paper is concerned with the central
question of whether MAPK pathway activity within the PVN of
female rats is necessary for an anxiolytic phenotype. To address
this, we employed two distinct approaches: (1) acute pharmaco-
logically-induced (i.e. application of exogenous OXT), and (2)
long-term physiologically-induced (i.e. lactation) anxiolysis and
assessed their effects on the MAPK pathway within the PVN
(Figure 1).
Results
Experiment 1. Effect of intra-PVN infusion of OXT on
anxiety-related behaviour in virgin and lactating rats:
effects of pre-treatment with the MEK1/2 inhibitor,
U0126
In virgin rats, ANOVA did not reveal a significant effect of
either bilateral infusion of U0126 (F1,29=2.21; p=0.15) or OXT
(F1, 29=3.59; p=0.068) directly into the PVN on the relative time
spent in the light box of the light dark box (LDB). However,
separate analyses revealed a significant anxiolytic effect of vehicle/
OXT infusion (MWU; p=0.009 versus vehicle/vehicle group;
Fig. 2A) while there were no significant differences between the
three other groups. This effect was not paralleled by altered
locomotor activity as the number of line-crosses in the dark
compartment did not differ between the treatment groups (data
not shown).
Figure 1. Schematic representation of PVN-enriched hypothalamic tissue that was extracted for western blot analyses. Scale bar:
1 mm.
doi:10.1371/journal.pone.0037060.g001
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MEK1/2 inhibition on anxiety was observed in lactating rats
(F1,32=11.3, p=0.002). Specifically, U0126 treatment increased
basal anxiety in lactating rats (p,0.05 versus vehicle/vehicle,
Fig. 2B) without altering locomotor activity (data not shown).
Interestingly, bilateral intra-PVN infusion of synthetic OXT did
not affect anxiety in lactation (F1,32=3.08; p=0.089; Fig. 2B).
Experiment 2. Determination of basal and OXT-induced
MEK 1/2 and ERK1/2 activation within the PVN in virgin,
pregnant, and lactating rats
To determine whether reproductive status altered hypothalamic
MEK1/2 activation within the PVN, we analysed phosphorylated
MEK1/2 (pMEK1/2) levels relative to total MEK and protein
content in virgin and lactating (LD8) rats. pMEK1/2 levels
appeared to be 2467% higher in the cytoplasmatic fraction of
lactating rats than in virgin rats (p=0.04), and this applied to both
the pMEK/MEK and the pMEK/GAPDH ratio (Fig. 3). The
MEK/GAPDH ratio was similar in both groups, indicating that
the increased pMEK1/2 concentration is due to increased
phosphorylation, rather than to increased MEK synthesis, during
lactation. There were no effects of reproductive state on nuclear
MEK phosphorylation or content (data not shown).
Cytoplasmatic pERK1, but not pERK2, levels relative to both
loading controls (GAPDH and b-tubulin; data not shown) tended
to decrease in late-pregnant rats, and this effect reached
significance in lactating rats (to 51.4% relative to virgin;
F2,17=6.65; p=0.009; Fig. 4A). In parallel, the nuclear pERK1
content increased in lactating rats as measured relative to the
TATA box binding protein (TBP) loading control (1.6-fold
increase relative to levels in virgins; F2,17=5.68; p=0.016;
Fig. 4B3). This was accompanied by a similar increase of the
ERK1/TBP ratio (1.5-fold increase; F2,17=4.17; p=0.04;
Fig. 4B4). The ratio of pERK1/ERK1 was, in contrast, constant
in both cellular compartments (Figs. 4A2, 4B2), indicating that in
lactating rats, but not in late-pregnant rats, ERK1 is phosphor-
ylated, and subsequently translocates to the nucleus.
Infusion of OXT (1 nmol icv) increased pMEK levels, relative to
total MEK and protein content, by 2469% in the cytoplasmatic
Figure 2. The effects of acute bilateral PVN administration of
vehicle (Ringer solution, pH 7.4; Veh), or OXT (0.01 nmol/
0.5 ul) after intra-PVN pre-treatment with either vehicle
(DMSO) or the MEK 1/2 inhibitor, U0126 (0.5 nmol/0.5 ul) on
time spent in the light compartment of the LDB in (A) virgin
rats and (B) lactation day 8 rat dams. Data represent mean + sem
(n=7–12 per group). Two-way ANOVA was performed followed by
Fisher’s LSD post-hoc tests where appropriate. * p,0.05 compared with
vehicle treatment and # p,0.05 compared with respective virgin
group.
doi:10.1371/journal.pone.0037060.g002
Figure 3. MEK phosphorylation as function of reproductive
status in female rats. A, Representative blot of cytoplasmatic pMEK
and MEK from PVN protein extracts from virgin and lactating rats. B,
Cytoplasmatic pMEK levels were higher in the PVN of lactating rats
when compared with total MEK and total protein (as measured by
GAPDH amount), whereas total MEK levels were similar in both groups.
Data relative to virgin control value of 1. Mann-Whitney U-test, *
p,0.05.
doi:10.1371/journal.pone.0037060.g003
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lactating rats. A1, B1; representative cytoplasmatic and nuclear blots. A2, ERK phosphorylation in the cytoplasm tended to increase during
pregnancy and lactation when corrected for the amount of total kinase, although not significantly. A3, cytoplasmatic pERK levels did not change
during peripartum, when corrected for total protein amount (as measured by GAPDH levels). A4, Cytoplasmatic ERK1 concentration decreased during
lactation, when compared with total protein amount. B2, Nuclear pERK/ERK ratio is constant over the peripartum period. B3, pERK1 levels were
elevated in the nuclear fraction of lactating animals, when corrected for total amount of protein (as measured by TBP levels). B4, Nuclear total ERK1
levels were elevated in lactating rats. ANOVA was performed followed by Tukey’s and Bonferroni’s post-hoc tests where appropriate. All data are
relative to virgin control values (set to 1). * p,0.05 and ** p,0.01 compared with respective virgin group. Vir, virgin; Lact, lactating.
doi:10.1371/journal.pone.0037060.g004
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ingly, MEK activation was not accompanied by increased ERK1/
2 phosphorylation in virgins (Fig. 5). In lactating rats, where brain
OXT activity is already high, pMEK levels were decreased in
response to icv OXT (22769%; p=0.049 versus lactating,
vehicle-treated rats; Fig. 5). Again, the icv OXT infusion did not
alter pERK1/2 levels neither in the cytoplasm nor in the nucleus.
Experiment 3. Effects of blockade of the MAP kinase
pathway on basal and OXT-induced ERK1/2 kinase
activation within the hypothalamus of virgin and
lactating rats
As the OXT-induced phosphorylation of MEK1/2 appeared to
be uncoupled from the phosphorylation of ERK1/2, we inhibited
the activity of pMEK1/2 pharmacologically with U0126 (1 nmol,
icv) to determine whether pMEK1/2 exerts ERK1/2 phosphor-
ylation activity in the PVN of female rats. Treatment with U0126
lowered basal pERK1/2 concentrations to a similar extent in both
virgin and lactating rats (where pMEK1/2 had a profound effect
on basal anxiety-like behaviour; Fig. 2B) to 52.9% (pERK1) and
58.4% (pERK2) of control (vehicle, DMSO-treated rats) levels
(p=0.019; Fig. 6), indicating that pMEK1/2 is indeed a kinase of
ERK1/2.
Discussion
In the present study we reveal that the complex neuronal
adaptations, observed during lactation, include a tonic activation
of MEK1/2 and ERK1 within the hypothalamic PVN. These
effects were specific to lactation as no alterations in MAPK
pathway activity in late pregnancy were observed. Acute local
blockade of this MAPK signalling pathway in lactating rats caused
a profound anxiogenic phenotype, indicating its involvement in
lactation-associated anxiolysis. In addition, central OXT infusion
resulted in activation of MEK1/2, as well as in anxiolysis in virgin
rats, while in lactating rats OXT reduced, rather than increased,
MEK1/2 phosphorylation without influencing anxiety-related
behaviour. This suggests that in lactating rats, OXT might recruit
additional pathways that could play a role in anxiolysis as
endogenous levels are already high. Taken together, these results
have implications regarding the mechanisms underlying the
emotional alterations observed at peripartum, the reduced anxiety
level, and increased calmness observed in breast-feeding women in
particular.
The anxiolytic effect of endogenous brain OXT has been well-
documented in female rats during the peripartum period
[12,18,19]. A major site of synthesis and release of endogenous
OXT is the PVN, and both aspects have been demonstrated to be
up-regulated during lactation [8,20,21]. Here, we also demon-
strate, for the first time, an anxiolytic effect of synthetic OXT
directly within the PVN of virgin female rats. These results,
together with our recent findings in male rats [3,22], suggest that
an increase in the availability of extracellular OXT within the
PVN, either by local neuronal release or local infusion, results in
anxiolysis independent of sex. The effects of synthetic OXT on
anxiolysis were recently shown to be highly peptide-specific [3],
and not due to actions at the receptor for the closely related
neuropeptide vasopressin. Indeed, vasopressin has been consis-
tently shown to increase anxiety [23].
The anxiolytic effect of intra-PVN OXT in virgin rats was
abolished by prior administration of a MEK inhibitor, U0126,
supporting recent findings in males [3,24,25]. This suggests that
MEK mediates OXT-induced anxiolysis within the PVN in both
male and female rats.
Our results presented here demonstrate that there is an
activation of the MEK1/2 – ERK1 signalling cascade in the
PVN during lactation. This was indicated by the profound
anxiogenic effect of blockade of this pathway only in lactating rats,
Figure 5. The effect of acute icv administration of oxytocin (OXT) on MEK and ERK phosphorylation in the cytoplasmatic fraction of
PVN tissue of virgin and lactating rats. In virgins, OXT induced the phosphorylation of MEK, but not ERK, while in lactating rats OXT induced
dephosphorylation of MEK, without affecting pERK levels. Total MEK and ERK levels did not change (not shown). Data are relative to vehicle (Veh)
control groups for each reproductive state. Mann-Whitney U-test, * p,0.05.
doi:10.1371/journal.pone.0037060.g005
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from mid-lactating rats compared with virgins, and by increased
pERK1 and ERK1 levels in the nucleus; indicative of nuclear
translocation. Our analysis of ERK phosphorylation and translo-
cation, being the final results of MAPK activation, in both
pregnant and lactating rats further showed that MAPK signalling
only changes after giving birth; when the robust alterations in
anxiety levels occur [9,10]. Moreover, in contrast to virgin and
male [3] rats, where acute OXT administration resulted in an
increased pMEK/MEK ratio, OXT did not cause further
activation of MEK1/2 in lactating rats, and was concomitantly
without effect on anxiety-like behaviour. One might suggest that,
as the endogenous OXT tone is already at a high level in the
peripartum period [21], application of exogenous OXT does not
elevate MEK activity further. Such a ceiling effect is likely not the
only explanation, however, because OXT even reduced pMEK
levels in lactating rats, indicating that OXT recruits one or more
additional intracellular pathways in these animals leading to,
amongst others, inhibition of MEK1/2. Although the tissue
samples used for Western Blot analyses are PVN-enriched, and
U0126 and/or OXT were infused into the PVN for the
behavioural studies, we cannot completely rule out the possibility
that the observed effects are partially mediated by surrounding
hypothalamic regions, such as the neighbouring ventromedial
hypothalamus. However, OXT infusions here have been shown to
modulate sexual behaviour, rather then anxiety-related behaviour
[26]. Taken together with the spatial restriction observed following
small volume infusions into the brain [27,28], this supports the
conclusion that the role of hypothalamic MAPK activity in anxiety
is predominantly localised within the PVN.
While MEK phosphorylation, as measured by western blotting,
and MEK activity-dependent anxiety-like behaviour were in
perfect agreement, ERK phosphorylation was negligibly influ-
enced by icv OXT infusion. This is quite remarkable, as ERK1/2
are the only known targets of MEK1/2 in the brain to date.
Interactions of MEK with its substrates (and upstream kinases) are
organised by several scaffolding proteins including KSR [29],
MP1 [30], and disc-large [31]. It seems reasonable to assume that
MEK, being part of a large signalling complex anchored to
scaffolding proteins, could physically interact with substrates other
than ERK1/2 as well. Indeed, in human monocytes, a MEK2 –
PI3Kd pathway has been identified that operates independently
from ERK, and serves to stimulate the production of an
endogenous interleukin 1 receptor antagonist [32]. Other proteins
that directly interact with MEK are the TGF-b receptor type II in
a lymphoma cell line [33], and tumor suppressor WOXI in
lysosomes of Jurkat cells (promotes apoptosis in T cell leukemia
[34]). Also, MEK has been found to translocate to and from the
nucleus, where it directly phosphorylates the transcription factor
MyoD in differentiating myoblasts, thus influencing gene tran-
scription [35]. Finally, MEK has been shown to bind the nuclear
receptor peroxisome proliferator-activated receptor c (PPARc),
then to export it out of the nucleus, and hence, to reduce PPARc-
controlled gene expression [36]. It is tempting to speculate that in
PVN neurons several pMEK1/2 substrates exist as well, and that
these are recruited following stimulation with OXT to bring about
anxiolytic effects.
Although ERK1/2 phosphorylation appeared not to be
controlled by OXT in the PVN of virgin and lactating female
rats, our experiments with U0126, a blocker of pMEK1/2 activity,
showed nevertheless that pMEK1/2 is involved in the control of
‘‘basal’’ (i.e. not stimulated with OXT) ERK1/2 phosphorylation.
This shows that our protocols allow for the detection of subtle
changes in ERK phosphorylation status, and that the lack of ERK
phosphorylation in response to OXT treatment is not caused by
methodological issues. In support of this, using the very same
protocols as described here, we observed changes in pERK levels
in the striatum of male rats that were exposed to social stimuli
(Lukas, Neumann, Van den Burg, unpublished).
The only effect of reproduction on pERK we observed was the
apparent translocation of pERK1 (but not pERK2) to the nucleus
in lactating animals. We believe this accommodates the changes at
the gene expression level necessary to induce neuroplasticity and
stable rewiring of the neural circuitries that occur in lactation,
resulting in physiological, psychological, and behavioural adapta-
tions. Thus, it has consistently been reported that the PVN
undergoes major morphological alterations during the peripartum
period. This has been associated with increased OXT activity,
both in the supraoptic nucleus and PVN [37,38,39]. The
differential effect of reproductive status on ERK1 and ERK2
adds to the notion that these two closely related MAP kinases exert
separate functions in the brain. It has for long been believed that
ERK1 and ERK2 are redundant, but elegant experiments
employing genetic strategies (such as the generation of knockdown,
knockout, and conditional knock-out mice) have revealed espe-
cially ERK2-specific effects on learning and memory [40], as well
as on the regulation of complex behaviour, including social
behaviour [2]. Although ERK1 was reported not to influence
learning and memory [41], a later study using ERK1 knockout
mice revealed a specific role of ERK1 synaptic plasticity and drug
addiction in the striatum [42]. Therefore, the translocation that we
observed in lactating rats may, at least in part, underlie the
plasticity seen within the PVN of lactating dams, in addition to the
anxiolysis.
In conclusion, we have shown that the peripartum period in rats
is accompanied by complex alterations in MEK – ERK signalling,
which has important implications for anxiety-like behaviour. We
favour a model in which both MEK1/2 and ERK1 are necessary
to develop the anxiolytic phenotype observed during lactation (on
the basis of increased MEK phosphorylation and ERK translo-
cation in lactating animals). Some other MEK-controlled factor(s)
must be responsible for the anxiolytic effect of OXT in virgin rats,
because of lack of ERK1/2 phosphorylation. In contrast, in
lactating rats there might be a switch in the recruitment of
intracellular pathways coupled to the OXT receptor, as pMEK1/
2 levels were down-regulated. Taken together, these results
Figure 6. The effect of acute icv administration of U0126 on
ERK1/2 phosphorylation in the cytoplasmatic fraction of the
PVN of lactating rats. U0126 reduced phosphorylation of both ERK1
and ERK2; highly similar results were obtained in virgin animals (not
shown). Data are expressed relative to respective vehicle (Veh) control
group. Mann-Whitney U-test, * p,0.05. Tub, b-tubulin.
doi:10.1371/journal.pone.0037060.g006
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induced, anxiolysis in virgins, and the maintenance of an
anxiolytic phenotype during lactation.
Materials and Methods
Animals
Adult female Wistar rats (Charles River, Germany, 220–260 g
body weight at the beginning of the experiment) were housed
under standard laboratory conditions in groups of 3 to 4 (12 h
light:dark cycle, 22–24uC, lights on at 06.00 h, food and water ad
libitum). All experiments were performed between 08:00–11:00,
approved by the government of the Oberpfalz, Germany, and
performed in accordance with the Guide for the Care and Use of
Laboratory Animals by the National Institutes of Health,
Bethesda, MD, USA.
After at least one week of habituation, mating with a sexually-
experienced male (300–350 g) was performed. Confirmation of
pregnancy was accomplished by observing the presence of sperm
in vaginal smears and designated as pregnancy day 1.
Surgical procedures
All surgical stereotaxic procedures were performed under
isoflurane anaesthesia and semi-sterile conditions on pregnancy
day (PD) 14, lactation day (LD) 2 and in age-matched virgin rats.
Following surgery, rats received a subcutaneous (s.c.) injection of
antibiotic (0.03 ml enrofloxacin; 100 mg/1 ml Baytril, Bayer).
Animals were allowed to recover before undergoing behavioural
or MEK1/2 – ERK1/2 phosphorylation assessment six days after
surgery (i.e. PD 20 or LD 8). Rats were housed singly after surgery
and handled daily to habituate them to the respective central
infusion procedure and to avoid non-specific stress responses
during the experiment.
For analysis of the hypothalamic MAPK pathway in virgin,
pregnant and lactating rats under the influence of icv vehicle,
OXT (Sigma), or MEK1/2 inhibitor (U0126, Sigma) infusion, an
indwelling icv guide cannula (stainless steel, 21 G, 12 mm long)
was stereotaxically implanted 2 mm above the right lateral
ventricle (AP: 21.0 mm bregma, ML: +1.6 mm lateral, DV:
+1.8 mm below the surface of the skull; [43]) as previously
described [3,44].
For analysis of local effects of OXT within the PVN on anxiety-
related behaviour, indwelling bilateral guide cannulas (stainless
steel, 23 G, 12 mm long) were implanted 2 mm above both the
left and right PVN (AP: 21.4 mm bregma, ML: 21.8 and
+2.1 mm lateral; DV: +6 mm below the surface of the skull; angle
10u; [3,43], and anchored to two stainless-steel screws using dental
acrylic. The guide cannulas were kept viable with dummy
cannulas, which were removed daily and cleaned during the
handling procedure.
Experimental protocols
Experiment 1. Effect of intra-PVN infusion of OXT on
anxiety-related behaviour in virgin and lactating rats, and
effects of local pre-treatment with the MEK1/2 inhibitor,
U0126. The following experiment was performed in order to (i)
compare the effects of OXT infused bilaterally into the PVN on
anxiety-related behaviour in virgin and lactating rats and (ii) test
for a possible involvement of the MEK1/2 – ERK1/2 cascade in
the anxiolytic effect of both, OXT and lactation. Thus, conscious
virgin and lactating rats received two subsequent bilateral PVN
infusions. They were pre-treated with either vehicle (0.5 ml; 10%
DMSO in Ringer solution, pH 7.4, Braun) or the MEK inhibitor
U0126 (0.5 nmol/0.5 ml) bilaterally within the PVN 5 min prior to
infusion of either vehicle, or OXT (0.01 nmol/0.5 ml) to assess
four different groups (vehicle/vehicle, vehicle/OXT, U0126/
vehicle or U0126/OXT). After each infusion, the cannulas were
kept in place for 30 s to allow local substance diffusion. Anxiety-
related behaviour was assessed in the light-dark box (LDB) 10 min
later. The doses were chosen based on previous studies [3].
Experiment 2. Determination of basal and OXT-induced
MEK1/2 and ERK1/2 activation within the hypothalamus
of virgin, pregnant, and lactating rats. To assess the impact
of reproductive status under basal and acute icv OXT conditions
on hypothalamic MEK1/2 and ERK1/2 activation, conscious
well-handled virgin, pregnant (PD20), and lactating (LD8) rats
received either an acute vehicle (5 ml; Ringer solution, pH 7.4,
Braun) or OXT (1 nmol) infusion. After icv infusion, the cannulas
were kept in place for 30 s to allow local substance diffusion. Ten
minutes later, rats were decapitated and the hypothalami
dissected, immediately frozen, and stored at 220uC until required.
The hypothalamus was dissected rostrally at the level of the optic
chiasm, and caudally through the median eminence. Laterally, the
lateral ventricle was used as a landmark to remove the most lateral
parts of the hypothalamus. Dorsally, the third ventricle represent-
ed the top most level of the PVN-enriched region. The
suprachiasmatic and remaining part of the supraoptic nuclei were
also removed. This results in a hypothalamic tissue block
containing mostly the PVN with some bed nucleus of the stria
terminalis, medial preoptic area, and the anterior hypothalamic
nuclei (Fig. 1 and [43]).
Experiment 3. Effects of blockade of MEK1/2 activity on
basal and OXT-induced ERK1/2 activation within the
hypothalamus. To assess if icv pre-treatment with the
MEK1/2 kinase inhibitor, U0126, reduced basal or OXT-induced
ERK1/2 activation in virgin or lactating (LD8) rats, the following
groups were compared: vehicle/vehicle, U0126 (1 nmol)/vehicle,
vehicle/OXT (1 nmol) or U0126/OXT. The icv infusions were
10 min apart, and 10 min after the second infusion, the
hypothalami were isolated as described in Experiment 2.
Light-dark box
To assess the effects of OXT and MEK inhibitor infusions
bilaterally in the PVN of virgin or lactating rats on anxiety-related
behaviour, the animals were tested in the LDB seven days after the
implantation of the guide cannulas (i.e. LD 8 or equivalent in age-
matched virgins) and 10 min after the last drug infusion. The LDB
test was performed as previously described [22,44]. Briefly, the
LDB setup consisted of two compartments; one lit compartment
(40650 cm, 350 lux; light box) and one dark compartment
(40630 cm, 70 lux). The floors in each compartment were divided
into squares (10610 cm) and the compartments were connected
via a small opening (7.567.5 cm) enabling transition between the
compartments. Rats were placed in the dark compartment and
line-crosses, time spent in each compartment, rearings, and
latency to first light compartment entry during the 5-min test,
were assessed on-line via a camera located above the box. The
time spent in the light box by the vehicle/vehicle group was set to
100% for each experiment.
Western blot analysis of protein phosphorylation
Cytoplasmatic and nuclear proteins were extracted using a
protein extraction kit (Active Motif, Rixensart, Belgium). Briefly,
single hypothalamic tissue blocks were homogenised in 300 ml
hypotonic buffer (supplemented with 0.1 mM DTT, 0.1 mM
detergent, phosphatase and protease inhibitors as included in the
kit), and incubated on ice for 15 min. Following centrifugation
(10 min, 850 g, 4uC), the supernatant containing cytoplasmatic
MAPK Pathway Vital for Anxiolysis in Female Rats
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resuspended in 200 ml of hypotonic buffer (supplemented only
with phosphatase and protease inhibitors) and incubated on ice for
15 min. Then 50 ml/ml of detergent was added, the mixture
vigorously vortexed and centrifuged (3 min, 14,000 g, 4uC). The
supernatant was collected and pooled with the supernatant
collected earlier to an end volume of 500 ml. The pellet was
washed once with ice-cold phosphate-buffered saline (PBS), to
wash away any remaining cytoplasmatic proteins, and resus-
pended in 100 ml complete lysis buffer, supplemented with DTT,
and phosphatase and protease inhibitors, as indicated by the
manufacturer. The samples were incubated on ice for 30 min,
then vortexed, centrifuged (10 min, 14,000 g, 4uC), and superna-
tants containing nuclear proteins collected. The protein concen-
trations were determined using the Pierce BCA Protein Assay Kit
(Thermo Scientific, Rockford, USA).
Thirty micrograms of each protein extract were separated on a
12,5% sodium dodecyl sulphate-polyacrylamide gel and trans-
ferred onto a nitrocellulose membrane (Bio-Rad). Non-specific
binding was blocked in Tris-buffered saline/0.1% Tween-20
(TBST, pH 7.6) supplemented with 5% bovine serum albumin
(BSA, Sigma) overnight at 4uC. Next, the blots were incubated
with a specific antibody against phosphorylated ERK1/2 or
MEK1/2 (1:1,000 each; Cell Signaling Technology, nrs 9101 and
9154, respectively). After 5 hours incubation at room temperature,
the blots were washed extensively with TBST, and incubated with
peroxidase-conjugated donkey anti-rabbit IgG (1:1,000; Amer-
sham, Little Chalfont, England) for 30 min. Then the blots were
washed again, and probed with an anti-b-tubulin (1:1,000, Cell
Signaling Technology), GAPDH, or TATA box binding-protein
(TBP) antibody (both 1:1,000; Abcam) as total protein loading
controls; b-tubulin and GAPDH for each cytoplasmic fraction,
and TBP for each nuclear fraction. After incubation overnight at
4uC, the blots were washed and treated with secondary antibody
as described above. Bands were visualised using ECL western blot
detection reagents (GE Healthcare, Little Chalfont, UK), and
images were acquired with the ChemiDoc XRS+ system (Bio-
Rad). After imaging, immunocomplexes were removed from the
blot with Re-Blot Plus Solution (Millipore), probed with anti-total
ERK1/2 or MEK1/2 antibodies (1:1,000; Cell Signaling Tech-
nology, nrs 9102 and 9122, respectively), and imaged as described
above to control for total amount of kinases loaded on the gel.
Verification of cannula placements
After the experimental procedure, the animals were sacrificed.
For verification of the placement of icv cannula, following
dissection of the hypothalamus, the rest of the brain was snap-
frozen in isopentane cooled to 232uC by dry-ice. Localisation of
the cannula tract was then performed using 40-mm cryosections
stained with Nissl and assisted with a brain atlas [43]. For PVN
cannula verification, blue dye was infused into the PVN as
described above, then the brain was snap-frozen in isopentane and
histological assessment performed as described for the icv cannulas
above. Only animals with correctly positioned cannulas were
included in the statistical analyses.
Statistical analyses
Signalling and behavioural data were analysed using either a
one-way or a two-way analysis of variance (ANOVA, factors
reproductive state x treatment, factors treatment 16treatment 2).
Behavioural data is expressed in comparison to vehicle-treated
groups of both virgins and lactating dams, as the experiments were
performed separately. Any overall statistical differences, which
were set at P,0.05, were further analysed using a Fisher’s post-hoc
test. Separate non-parametric Mann-Whitney U tests (MWU)
were performed. Data are expressed as group mean 6 S.E.M.
Statistical analyses were performed using SPSS for Windows
(version 16; SPSS Inc, Chicago, IL, USA).
Author Contributions
Conceived and designed the experiments: DAS IDN EHvB. Performed the
experiments: DAS BJ RM KH SK EHvB. Analyzed the data: DAS BJ
EHvB. Wrote the paper: DAS BJ IDN EHvB.
References
1. Davis S, Laroche S (2006) Mitogen-activated protein kinase/extracellular
regulated kinase signalling and memory stabilization: a review. Genes Brain
Behav 5 Suppl 2: 61–72.
2. Satoh Y, Endo S, Nakata T, Kobayashi Y, Yamada K, et al. (2011) ERK2
contributes to the control of social behaviors in mice. J Neurosci 31:
11953–11967.
3. Blume A, Bosch OJ, Miklos S, Torner L, Wales L, et al. (2008) Oxytocin reduces
anxiety via ERK1/2 activation: local effect within the rat hypothalamic
paraventricular nucleus. Eur J Neurosci 27: 1947–1956.
4. Chen J, Volpi S, Aguilera G (2008) Anti-apoptotic actions of vasopressin in H32
neurons involve MAP kinase transactivation and Bad phosphorylation. Exp
Neurol 211: 529–538.
5. Landgraf R, Neumann ID (2004) Vasopressin and oxytocin release within the
brain: a dynamic concept of multiple and variable modes of neuropeptide
communication. Front Neuroendocrinol 25: 150–176.
6. Bunck M, Czibere L, Horvath C, Graf C, Frank E, et al. (2009) A hypomorphic
vasopressin allele prevents anxiety-related behavior. PLoS One 4: e5129.
7. Murgatroyd C, Wigger A, Frank E, Singewald N, Bunck M, et al. (2004)
Impaired repression at a vasopressin promoter polymorphism underlies
overexpression of vasopressin in a rat model of trait anxiety. J Neurosci 24:
7762–7770.
8. Brunton PJ, Russell JA (2008) The expectant brain: adapting for motherhood.
Nat Rev Neurosci 9: 11–25.
9. Hillerer KM, Neumann ID, Slattery DA (2011) From Stress to Postpartum
Mood and Anxiety Disorders: How Chronic Peripartum Stress Can Impair
Maternal Adaptations. Neuroendocrinology.
10. Slattery DA, Neumann ID (2008) No stress please! Mechanisms of stress
hyporesponsiveness of the maternal brain. J Physiol 586: 377–385.
11. Carter CS, Altemus M, Chrousos GP (2001) Neuroendocrine and emotional
changes in the post-partum period. Prog Brain Res 133: 241–249.
12. Windle RJ, Kershaw YM, Shanks N, Wood SA, Lightman SL, et al. (2004)
Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain
regions associated with modulation of hypothalamo-pituitary-adrenal activity.
J Neurosci 24: 2974–2982.
13. Tomizawa K, Iga N, Lu YF, Moriwaki A, Matsushita M, et al. (2003) Oxytocin
improves long-lasting spatial memory during motherhood through MAP kinase
cascade. Nat Neurosci 6: 384–390.
14. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin
increases trust in humans. Nature 435: 673–676.
15. Labuschagne I, Phan KL, Wood A, Angstadt M, Chua P, et al. (2010) Oxytocin
attenuates amygdala reactivity to fear in generalized social anxiety disorder.
Neuropsychopharmacology 35: 2403–2413.
16. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M (2011) Oxytocin and
vasopressin in the human brain: social neuropeptides for translational medicine.
Nat Rev Neurosci 12: 524–538.
17. Viviani D, Charlet A, van den Burg E, Robinet C, Hurni N, et al. (2011)
Oxytocin selectively gates fear responses through distinct outputs from the
central amygdala. Science 333: 104–107.
18. Neumann ID, Torner L, Wigger A (2000) Brain oxytocin: differential inhibition
of neuroendocrine stress responses and anxiety-related behaviour in virgin,
pregnant and lactating rats. Neuroscience 95: 567–575.
19. Windle RJ, Shanks N, Lightman SL, Ingram CD (1997) Central oxytocin
administration reduces stress-induced corticosterone release and anxiety
behavior in rats. Endocrinology 138: 2829–2834.
20. Bosch OJ, Meddle SL, Beiderbeck DI, Douglas AJ, Neumann ID (2005) Brain
oxytocin correlates with maternal aggression: link to anxiety. J Neurosci 25:
6807–6815.
21. Neumann I, Ludwig M, Engelmann M, Pittman QJ, Landgraf R (1993)
Simultaneous microdialysis in blood and brain: oxytocin and vasopressin release
in response to central and peripheral osmotic stimulation and suckling in the rat.
Neuroendocrinology 58: 637–645.
22. Waldherr M, Neumann ID (2007) Centrally released oxytocin mediates mating-
induced anxiolysis in male rats. Proc Natl Acad Sci U S A 104: 16681–16684.
MAPK Pathway Vital for Anxiolysis in Female Rats
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e3706023. Landgraf R, Kessler MS, Bunck M, Murgatroyd C, Spengler D, et al. (2007)
Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus
on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 31: 89–102.
24. Strakova Z, Copland JA, Lolait SJ, Soloff MS (1998) ERK2 mediates oxytocin-
stimulated PGE2 synthesis. Am J Physiol 274: E634–641.
25. Zhong M, Yang M, Sanborn BM (2003) Extracellular signal-regulated kinase 1/
2 activation by myometrial oxytocin receptor involves Galpha(q)Gbetagamma
and epidermal growth factor receptor tyrosine kinase activation. Endocrinology
144: 2947–2956.
26. Bale TL, Davis AM, Auger AP, Dorsa DM, McCarthy MM (2001) CNS region-
specific oxytocin receptor expression: importance in regulation of anxiety and
sex behavior. J Neurosci 21: 2546–2552.
27. Jungling K, Seidenbecher T, Sosulina L, Lesting J, Sangha S, et al. (2008)
Neuropeptide S-mediated control of fear expression and extinction: role of
intercalated GABAergic neurons in the amygdala. Neuron 59: 298–310.
28. Tehovnik EJ, Sommer MA (1997) Effective spread and timecourse of neural
inactivation caused by lidocaine injection in monkey cerebral cortex. J Neurosci
Methods 74: 17–26.
29. Stewart S, Sundaram M, Zhang Y, Lee J, Han M, et al. (1999) Kinase
suppressor of Ras forms a multiprotein signaling complex and modulates MEK
localization. Mol Cell Biol 19: 5523–5534.
30. Pullikuth A, McKinnon E, Schaeffer HJ, Catling AD (2005) The MEK1
scaffolding protein MP1 regulates cell spreading by integrating PAK1 and Rho
signals. Mol Cell Biol 25: 5119–5133.
31. Maiga O, Philippe M, Kotelevets L, Chastre E, Benadda S, et al. (2011)
Identification of mitogen-activated protein/extracellular signal-responsive kinase
kinase 2 as a novel partner of the scaffolding protein human homolog of disc-
large. Febs J 278: 2655–2665.
32. Brandt KJ, Carpintero R, Gruaz L, Molnarfi N, Burger D (2010) A novel
MEK2/PI3Kdelta pathway controls the expression of IL-1 receptor antagonist
in IFN-beta-activated human monocytes. J Leukoc Biol 88: 1191–1200.
33. Chen G, Ghosh P, Longo DL (2011) Distinctive mechanism for sustained TGF-
beta signaling and growth inhibition: MEK1 activation-dependent stabilization
of type II TGF-beta receptors. Mol Cancer Res 9: 78–89.
34. Lin HP, Chang JY, Lin SR, Lee MH, Huang SS, et al. (2011) Identification of
an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell
Leukemia. Genes Cancer 2: 550–562.
35. Jo C, Cho SJ, Jo SA (2011) Mitogen-activated protein kinase kinase 1 (MEK1)
stabilizes MyoD through direct phosphorylation at tyrosine 156 during
myogenic differentiation. J Biol Chem 286: 18903–18913.
36. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, et al.
(2007) Interaction with MEK causes nuclear export and downregulation of
peroxisome proliferator-activated receptor gamma. Mol Cell Biol 27: 803–817.
37. Oliet SH (2002) Functional consequences of morphological neuroglial changes
in the magnocellular nuclei of the hypothalamus. J Neuroendocrinol 14:
241–246.
38. Theodosis DT, Poulain DA (1989) Neuronal-glial and synaptic plasticity in the
adult rat paraventricular nucleus. Brain Res 484: 361–366.
39. Theodosis DT (2002) Oxytocin-secreting neurons: A physiological model of
morphological neuronal and glial plasticity in the adult hypothalamus. Front
Neuroendocrinol 23: 101–135.
40. Satoh Y, Endo S, Ikeda T, Yamada K, Ito M, et al. (2007) Extracellular signal-
regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory;
ERK2 has a specific function in learning and memory. J Neurosci 27:
10765–10776.
41. Selcher JC, Nekrasova T, Paylor R, Landreth GE, Sweatt JD (2001) Mice
lacking the ERK1 isoform of MAP kinase are unimpaired in emotional learning.
Learn Mem 8: 11–19.
42. Mazzucchelli C, Vantaggiato C, Ciamei A, Fasano S, Pakhotin P, et al. (2002)
Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and
facilitates striatal-mediated learning and memory. Neuron 34: 807–820.
43. Paxinos G, Watson C (1998) The Rat Brain in Sterotaxic Coordinates (4th
edition). New York: Academic Press.
44. Slattery DA, Neumann ID (2010) Chronic icv oxytocin attenuates the
pathological high anxiety state of selectively bred Wistar rats. Neuropharma-
cology 58: 56–61.
MAPK Pathway Vital for Anxiolysis in Female Rats
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e37060